Medigen Biotechnology Corp. (TPEX:3176)

Medigen Biotechnology Revenue

Medigen Biotechnology had revenue of 284.74M TWD in the quarter ending June 30, 2026, a decrease of -21.08%. This brings the company's total for the last twelve months to 1.27B, down -22.05% year-over-year. In the year 2025, Medigen Biotechnology had annual revenue of 1.58B with 15.28% growth. That makes Medigen Biotechnology the 29,659th largest company in the world by revenue and 1,442nd in Taiwan.

• Revenue (ttm): 1.27B
• Revenue Growth: -22.05%
• P/S Ratio: 3.66
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 4.65B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Generic Drugs, Medical Beauty Products and Health Food Departments 700.07M 44.2%
• New Drug and Vaccine Development Department 613.17M 38.7%
• Nucleic Acid Test 269.26M 17.0%
• Cell Therapy Department 317.00K 0.0%

By Geography

Chart

• Taiwan 1.54B 97.6%
• Other 30.57M 1.9%
• Mainland China 7.21M 0.5%

Fiscal year ended Dec 31, 2025 See the full Medigen Biotechnology breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.58B	209.80M	15.28%
Dec 31, 2024	1.37B	214.98M	18.57%
Dec 31, 2023	1.16B	101.77M	9.64%
Dec 31, 2022	1.06B	-2.87B	-73.08%
Dec 31, 2021	3.92B	3.31B	537.17%

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 17, 2026

Data Sources Report a data error